AAPGV (Ascentage Pharma Group Ltd) רווח נקי למניה (EPS TTM)

The EPS YoY TTM growth trajectory on the GURU.Markets chart demonstrates profit dynamics, where the value of -12.70 corresponds to the current metric. Ascentage Pharma Group (AAPGV) capitalization relies on partner payments and drug sales in the US and China. The biotech company develops innovative cancer treatment methods, targeting oncology centers. Production is supported by the modernization of facilities for the manufacture of small-molecule drugs.
AAPGV (ascentage.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator captures the dynamics of the rolling annual earnings per share. By analyzing the 12-month EPS YoY percentage change, an investor tracks the growth rate of net income. The calculation is based on a comparison of the current TTM value with the same period last year. For Ascentage Pharma Group (AAPGV), such fluctuations reflect financial stability against the backdrop of oncology drug development costs. High volatility in this metric confirms the capital's dependence on clinical trial results.